https://orcid.org/0000-0002-9873-7507
Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Phil McEwan, Piotr Ponikowski, Tinevimbo Shiri, Giuseppe M. C. Rosano, Andrew J. S. Coats, Fabio Dorigotti, Antonio Ramirez de Arellano & Ewa A. Jankowska. (2023) Clinical and economic impact of ferric carboxymaltose treatment for iron deficiency in patients stabilized following acute heart failure: a multinational study. Journal of Medical Economics 26:1, pages 51-60.
Read now
Read now
Shanlian Hu, Limin Liu, Richard F. Pollock, Johannes Pöhlmann, Depei Wu & Yabing Zhang. (2022) Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose. Journal of Medical Economics 25:1, pages 561-570.
Read now
Read now
Richard F Pollock & Gorden Muduma. (2021) An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland. ClinicoEconomics and Outcomes Research 13, pages 9-18.
Read now
Read now
Irina Blumenstein, Satish Shanbhag, Peter Langguth, Philip A Kalra, Heinz Zoller & Wendy Lim. (2021) Newer formulations of intravenous iron: a review of their chemistry and key safety aspects – hypersensitivity, hypophosphatemia, and cardiovascular safety. Expert Opinion on Drug Safety 20:7, pages 757-769.
Read now
Read now
Xenophon Kassianides, Richard Bodington & Sunil Bhandari. (2021) An evaluation of ferric derisomaltose as a treatment for anemia. Expert Review of Hematology 14:1, pages 7-29.
Read now
Read now
Richard F. Pollock & Gorden Muduma. (2020) A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom. Journal of Medical Economics 23:7, pages 751-759.
Read now
Read now
Articles from other publishers (21)
Lu Yun, Zhu YuMei, Vallish BN, Qingu Tang & Chang Feng. (2023) The Efficacy, Safety, and Economic Outcomes of Using Ferric Derisomaltose for the Management of Iron Deficiency in China: A Rapid Health Technology Assessment. Cureus.
Crossref
Crossref
Huey Yi Chong, June Wai Yee Choon, Wei Chern Ang & Kenneth Kwing Chin Lee. (2023) Budget Impact Analysis of Ferric Derisomaltose for the Treatment of Iron-Deficiency in Malaysia. Malaysian Journal of Medicine and Health Sciences 19:4, pages 110-116.
Crossref
Crossref
Nicholas A. Kennedy, Maureen M. Achebe, Patrick Biggar, Johannes Pöhlmann & Richard F. Pollock. (2023) A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose. International Journal of Clinical Pharmacy 45:3, pages 604-612.
Crossref
Crossref
Tomohiko Sato & Ayumi Nojiri. (2023) Unanswered questions from the IRONMAN trial. The Lancet 401:10387, pages 1495.
Crossref
Crossref
Carmelo Aguirre, Itziar Palacios-Zabalza, Igor Ceruelo, Ainhoa Txintxurreta-Albizua & Montserrat García. (2023) Hypersensitivity reactions associated with iron isomaltoside and ferric carboxymaltose. European Journal of Internal Medicine 110, pages 117-119.
Crossref
Crossref
Yuhua Teng, Yule Jin, Huwei Wen, Xiuqun Ye & Changjin Liu. (2023) Spatial spillover effect of the synergistic development of inward and outward foreign direct investment on ecological well-being performance in China. Environmental Science and Pollution Research 30:16, pages 46547-46561.
Crossref
Crossref
Angel Lanas, Jane M Andrews, James Lau, Murat Toruner, Susan E Bromley & Ian M Gralnek. (2022) Management of iron‐deficiency anemia following acute gastrointestinal hemorrhage: A narrative analysis and review. Journal of Gastroenterology and Hepatology 38:1, pages 23-33.
Crossref
Crossref
Kuldeep Singh, Dimple Sethi Chopra, Dhandeep Singh & Nirmal Singh. (2022) Nano-formulations in treatment of iron deficiency anaemia: An overview. Clinical Nutrition ESPEN 52, pages 12-19.
Crossref
Crossref
Richard F. Pollock, Philip A. Kalra, Paul R. Kalra & Fozia Z. Ahmed. (2022) A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose. Advances in Therapy 39:10, pages 4678-4691.
Crossref
Crossref
Antonio Ramirez de Arellano, Nicholas Norton, Dana Enkusson, Linnea Oldsberg, Yvonne Thomson, Mathias Lilja & Aysegül Aksan. (2022) Cost-Effectiveness of Intravenous Iron Formulations in Patients with Iron Deficiency Anaemia and Inflammatory Bowel Disease, in a Swedish Regional Setting Using Real-World Tender Prices. GastroHep 2022, pages 1-10.
Crossref
Crossref
Xiaochun Pan, Yi Xiao & Zhengjun Liu. (2022) Equilibrium or imbalance? Regional variations and evolutionary traits of two-way FDI coordination level in Yangtze River economic belt. Frontiers in Environmental Science 10.
Crossref
Crossref
Jonathan W. Bazeley & Jay B. Wish. (2022) Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review. American Journal of Kidney Diseases 79:6, pages 868-876.
Crossref
Crossref
Michael Auerbach, Maureen M. Achebe, Lars L. Thomsen & Richard J. Derman. (2022) Efficacy and safety of ferric derisomaltose (FDI) compared with iron sucrose (IS) in patients with iron deficiency anemia after bariatric surgery. Obesity Surgery 32:3, pages 810-818.
Crossref
Crossref
Andrew P. Ambrosy, Stephan von Haehling, Paul R. Kalra, Emma Court, Sunil Bhandari, Theresa McDonagh & John G.F. Cleland. (2021) Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure. The American Journal of Cardiology 152, pages 138-145.
Crossref
Crossref
C. Bayerl. (2021) Intoleranz auf Eisen i. v.. Aktuelle Dermatologie 47:07, pages 291-292.
Crossref
Crossref
Michael Auerbach, David Henry & Thomas G. DeLoughery. (2021) Intravenous ferric derisomaltose for the treatment of iron deficiency anemia. American Journal of Hematology 96:6, pages 727-734.
Crossref
Crossref
Myles Wolf, Michael Auerbach, Philip A. Kalra, John Glaspy, Lars L. Thomsen & Sunil Bhandari. (2020)
Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The
FERWON‐IDA
/
NEPHRO
trials
. American Journal of Hematology 96:1.
Crossref
Crossref
Veronika Markova, Rebecka Hansen, Lars Lykke Thomsen, Anja Pinborg, Torben Moos & Charlotte Holm. (2020) Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy: protocol for a randomised, comparative, open-label trial. Trials 21:1.
Crossref
Crossref
Maureen M. Achebe, John Glaspy, Philip A. Kalra, Michael Auerbach, Lars L. Thomsen & Sunil Bhandari. (2020)
A 6 month extension trial evaluating safety and efficacy of ferric derisomaltose in patients with iron deficiency anemia: The
FERWON‐EXT
trial
. American Journal of Hematology 95:10.
Crossref
Crossref
Maureen Achebe & Thomas G. DeLoughery. (2020) Clinical data for intravenous iron – debunking the hype around hypersensitivity. Transfusion 60:6, pages 1154-1159.
Crossref
Crossref
Philip Schaffalitzky de Muckadell & Claes Christian Strom. (2020) Comment on ‘Reported Severe Hypersensitivity Reactions after Intravenous Iron Administration in the European Economic Area (EEA) Before and After Implementation of Risk Minimization Measures’. Drug Safety 43:5, pages 503-505.
Crossref
Crossref